Ceritinib - Novartis

Drug Profile

Ceritinib - Novartis

Alternative Names: LDK-378; NVP-LDK 378; NVP-LDK378-NX; Zykadia

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Diamines; Piperidines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Gastrointestinal cancer; Haematological malignancies; Malignant melanoma; Solid tumours; Thyroid cancer

Most Recent Events

  • 18 Jun 2018 Phase-II clinical trials in Malignant melanoma (Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT03501368)
  • 02 Apr 2018 University of Colorado and Novartis terminate a phase II trial in Gastrointestinal cancer (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA due to low patient enrolment (NCT02638909)
  • 24 Jan 2018 National Institute for Health and Clinical Excellence (NICE) approves ceritinib for ALK-positive non-small-cell lung cancer (First-line therapy; late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top